Lung Cancer: Non Small-Cell BRM Survival Comparision Data
Non Small-Cell BRM Survival Comparision Data
Immunotherapy seems to respond better to certain types of cancer. Non-small cell lung cancer is one in which we have seen some of the most encouraging results.
The following graph is a retrospective analysis of the effects of BRM therapy on non small-cell lung cancer from the combined tumor registry records, extensive stage disease, of the University of Mississippi Medical Center (UMC) and Mississippi Baptist Medical Center (MBMC), both located in Jackson, Mississippi; January 1985 – December 1988. More detailed information about this study is available.
Survival Time (Months)
Blue = Biological Response Modifiers all (72 patients)
Red Dotted = Mississippi Baptist Medical Center all (355 patients)
Purple = SEER* 1985-86 (5598 patients)
Green Dotted = No BRM (283 patients)
* Surveillance Epidemiology and End Results Registry of the National Cancer Institute, a national registry for survival comparison
This graph reveals:
(1) clear superiority of the BRM treated patients over other patients from the same institution
(2) clear superiority of BRM patients over SEER comparables
(3) a plateau in the late survival of the BRM treated patients not seen with the other treatment modalities.
Results derived by statistical comparison of the above survival curves.
BRM> no BRM
LOGRANK = 0.0001
WILCOXON = 0.0001
LOGRANK = 0.0003
WILCOXON = 0.0031
SEER > no BRM
LOGRANK = 0.0222
WILCOXON = 0.0007
A p. value of less than .05 is considered significant. By any of the three most commonly employed tests of statistical significance, BRM therapy produced marked statistical significance. The third test, the log rank test, is the most sensitive to late survival. and is generally considered to be the best of the tests.
Survival by Treatment (Months)
Orange = Mean
Red = Median
R – Radiotherapy only (209 patients)
C – Chemotherapy only ( 57 patients)
R/C – Radiotherapy and Chemotherapy (51 patients)
B/R – BRM and Radiotherapy (44 patients)
B/R/C – BRM and Radiotherapy and Chemotherapy (27 patients)
N- No Treatment (53 patients)
Note that the mean is much greater than the median. This occurs because a plateau is reached on the graph of patients receiving BRM therapy due to extraordinary survivors, some of which are still living at study end! These late survivors progressively increase the average (mean) survival to longer times. If you had lung cancer, would you want to be on the plateau?